Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size

Masoud, Sabran; Hu, Janice; Beasley, Georgia M.; Stewart, John H.; Mosca, Paul J.

doi:10.1245/s10434-019-07691-3

Cited by 24 publications

(28 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The impact of previous systemic therapy on response to T-VEC thus remains an open question [26]. A retrospective analysis of 27 melanoma patients treated with T-VEV found a decreased ORR for pre-treated patients without describing details of these patients [13]. Our data suggest that some patients' clinical course may benefit from prior therapy with T-VEC and may even pave the way to long-term response.…”

Section: Discussionmentioning

confidence: 78%

“…The two-center retrospective analysis including 40 patients in USA reported increased overall survival and PFS in patients with smaller tumors [14]. The retrospective single-center analysis in 27 patients demonstrated decreased efficacy of T-VEC with increasing lesion size [13]. However, a general definition for tumor burden does not exist.…”

Section: Discussionmentioning

confidence: 99%

“…One patient with in-transit metastatic melanoma, stage IIIB (patient No 1) received T-VEC after prior targeted therapy with BRAF/MEK inhibitor and obtained a longlasting, complete response. Another patient (patient No 10) with M1a stage melanoma received prior anti-PD1-therapy, which led to a regression of lymph-node metastases, whereas in-transit metastases showed loco-regional resistance to Four patients with advanced melanoma, stage M1b-M1c, who had received one or more prior systemic therapies were treated with T-VEC (patients [11][12][13][14]. These patients suffered from a loco-regional progression, while distant metastases had been stable or regressive during prior systemic treatment.…”

Section: Efficacy-response Ratementioning

confidence: 99%

“…Yet, published data about use of T-VEC in routine clinical practice are scarce. There are four recent case series from the US that report on use of T-VEC in three single institutions and one two-center retrospective analysis [11][12][13][14]. A recent multicenter chart review analyzed data from 27 patients treated with T-VEC in routine clinical practice in Germany [15].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients

Fröhlich

Niebel

Fietz

et al. 2020

Cancer Immunol Immunother

View full text Add to dashboard Cite

Background Resistance to immune checkpoint blockade and targeted therapy in melanoma patients is currently one of the major clinical challenges. With the approval of talimogene laherparepvec (T-VEC), oncolytic viruses are now in clinical practice for locally advanced or non-resectable melanoma. Here, we describe the usage of T-VEC in stage IVM1b-M1c melanoma patients, who achieved complete remission or stable disease upon systemic treatment but suffered from a locoregional recurrence. To our knowledge, there are no case reports so far describing T-VEC as a means to overcome acquired resistance to immune checkpoint blockade or targeted therapy. Methods All melanoma patients in our department treated with T-VEC in the period of 2016-2018 were evaluated retrospectively. Data on clinicopathological characteristics, treatment response, and toxicity were analyzed. Results Fourteen melanoma patients were treated with T-VEC in our center. Six patients (43%) received T-VEC first-line. In eight patients (57%), T-VEC followed a prior systemic therapy. Three patients with M1b stage and one patient with M1c stage melanoma were treated with T-VEC. These patients suffered from loco-regional progress, whilst distant metastases had regressed during prior systemic treatment. 64% of patients showed a benefit from therapy with T-VEC. The durable response rate was 36%. Conclusion T-VEC represents an effective and tolerable treatment option. This is true not only for loco-regionally advanced melanoma patients, but also for patients with stable or regressive systemic metastases who develop loco-regionally acquired resistance upon treatment with immune checkpoint blockade or targeted therapy. A sensible selection of suitable patients seems to be crucial.

show abstract

Section: Discussionmentioning

confidence: 78%

Section: Discussionmentioning

confidence: 99%

Section: Efficacy-response Ratementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients

Fröhlich

Niebel

Fietz

et al. 2020

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…T-VEC has been approved by the US FDA for the treatment of melanoma [113]. In a recent study, the ORR among patients with in-transit melanoma metastasis treated with T-VEC was 40.7% [114].…”

Section: Improving the Safety Of Ovsmentioning

confidence: 99%

Development of oncolytic virotherapy: from genetic modification to combination therapy

et al. 2020

View full text Add to dashboard Cite

Oncolytic virotherapy (OVT) is a novel form of immunotherapy using natural or genetically modified viruses to selectively replicate in and kill malignant cells. Many genetically modified oncolytic viruses (OVs) with enhanced tumor targeting, antitumor efficacy, and safety have been generated, and some of which have been assessed in clinical trials. Combining OVT with other immunotherapies can remarkably enhance the antitumor efficacy. In this work, we review the use of wild-type viruses in OVT and the strategies for OV genetic modification. We also review and discuss the combinations of OVT with other immunotherapies.

show abstract

Current strategies of virotherapy in clinical trials for cancer treatment

Lin

Zhao

Zhong

2021

Journal of Medical Virology

View full text Add to dashboard Cite

As a novel immune‐active agent for cancer treatment, viruses have the ability of infecting and replicating in tumor cells. The safety and efficacy of viruses has been tested and confirmed in preclinical and clinical trials. In the last decade, virotherapy has been adopted as a monotherapy or combined therapy with immunotherapy, chemotherapy, or radiotherapy, showing promising outcomes against cancer. In this review, the current strategies of viruses used in clinical trials are classified and described. Besides this, the challenge and future prospects of virotherapy in the management for cancer patients are discussed in this review.

show abstract

Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size

Cited by 24 publications

References 16 publications

Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients

Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients

Development of oncolytic virotherapy: from genetic modification to combination therapy

Current strategies of virotherapy in clinical trials for cancer treatment

Contact Info

Product

Resources

About